<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Journal of Carcinogenesis - Latest articles</title>
		<link>http://www.carcinogenesis.com</link>
		<description>The latest articles from Journal of Carcinogenesis (ISSN 1477-3163) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/7/1/2"/>			    
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/7/1/1"/>			    
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/6/1/19"/>			    
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/6/1/18"/>			    
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/6/1/17"/>			    
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/6/1/16"/>			    
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/6/1/15"/>			    
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/6/1/14"/>			    
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/6/1/13"/>			    
            
				    <rdf:li rdf:resource="http://www.carcinogenesis.com/content/6/1/12"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.carcinogenesis.com/content/7/1/2">
            
            <title>Implications of tyrosine phosphoproteomics in cervical carcinogenesis</title>
			<description>Background:
Worldwide cervical cancer remains a leading cause of mortality from gynecologic malignancies. The link between cervical cancer and persistent infection with HPV has been established. At a molecular level little is known about the transition from the precancerous state to invasive cancer. To elucidate this process, cervical biopsies from human specimens were obtained from precancerous state to stage III disease. 
Methods:
Cervical biopsies were obtained from patients with a diagnosis of cervical cancer undergoing definitive surgery or staging operation. Biopsies were obtained from patients with precancerous lesions at the time of their excisional procedure. Control samples were obtained from patients undergoing hysterectomy for benign conditions such as fibroids.  Samples were subjected to proteomic profiling using two dimensional gel electrophoresis with subsequent trypsin digestion followed by MALDI-TOF protein identification. Candidate proteins were then further studied using western blotting, immunoprecipitation and immunohistochemistry.
Results:
Annexin A1 and DNA-PKcs were found to be differentially expressed. Phosphorylated annexin A1 was up regulated in diseased states in comparison to control and its level was strongly detected in the serum of cervical cancer patients compared to controls. DNA-PKcs was noted to be hyperphosphorylated and fragmented in cancer when compared to controls. By immunohistochemistry annexin A1 was noted in the vascular environment in cancer and certain precancerous samples. 
Conclusions:
This study suggests a probable role for protein tyrosine phosphorylation in cervical carcinogenesis. Annexin A1 and DNA -PK cs may have synergistic effects with HPV infection. Precancerous lesions that may progress to cervical cancer may be differentiated from lesions that will not base on similar immunohistochemical profile to invasive squamous cell carcinoma.</description>
			<link>http://www.carcinogenesis.com/content/7/1/2</link>
			
			 	<dc:creator>Bernice L Robinson-Bennett, James DeFord, Concepcion Diaz-Arrastia, Lyuba Levine, Hui-Qui Wang, Edward V Hannigan and John Papaconstantinou</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2008, 7:2</dc:source>
			<dc:date>2008-07-17</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-7-2</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.carcinogenesis.com/content/7/1/1">
            
            <title>BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC</title>
			<description>BachgroundActivating BRAF mutations are present in approximately 50% of melanomas. Although different downstream target genes of the most common mutant V600E have been identified, the contribution of activating BRAF mutations to malignant transformation needs further clarification.
Methods:
Microarray gene analysis was performed for human melanoma cell lines harboring BRAFV600E mutations in comparison to cell lines without this mutation.
Results:
This analysis revealed a more than two fold down-regulation of 43 and an increase of 39 gene products. BAALC (Brain and acute Leukaemia, cytoplasmatic) was most prominently regulated, since it was up-regulated in mutated cell lines by a mean of 11.45. Real time PCR analyses with RNA from melanoma cell lines (n = 30) confirmed the BRAF-activation dependent up-regulation of BAALC.
Conclusion:
BAALC, which has been associated with cell dedifferentiation and migration, may function as a downstream effector of activating BRAF mutations during melanomagenesis.</description>
			<link>http://www.carcinogenesis.com/content/7/1/1</link>
			
			 	<dc:creator>David Schrama, Gunhild Keller, Roland Houben, Christian G Ziegler, Claudia S Vetter-Kauczok, Selma Ugurel and J&#252;rgen C Becker</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2008, 7:1</dc:source>
			<dc:date>2008-07-16</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-7-1</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.carcinogenesis.com/content/6/1/19">
            
            <title>Comparative evaluation of antiproliferative, antiangiogenic and apoptosis inducing potential of black tea polyphenols in the hamster buccal pouch carcinogenesis model</title>
			<description>Background:
To evaluate the relative chemopreventive efficacy of two black tea polyphenols, Polyphenon-B [P-B] and BTF-35 on 7,12-dimethylbenz [a]anthracene (DMBA)-induced hamster buccal pouch (HBP) carcinogenesis.
Methods:
Hamsters were divided into 6 groups. The right buccal pouches of animals in groups 1&#8211;3 were painted with 0.5% of DMBA three times a week for 14 weeks. While hamsters in group 1 received no further treatment, animals in groups 2 and 3 received diet containing 0.05% P-B and BTF-35 respectively, four weeks before DMBA painting that was continued until the end of the experiments. Animals in groups 4 and 5 were given P-B and BTF-35 alone respectively as in groups 2 and 3. Group 6 animals served as the untreated control. All the animals were sacrificed after 18 weeks. The expression of p21, cyclin D1, glutathione S-transferase pi (GST-P), nuclear factor kappa B (NF-&#954;B), Bcl-2, Bax, cytochrome C, caspase-3, caspase-9, poly(ADP-ribose) polymerase (PARP), cytokeratins and vascular endothelial growth factor (VEGF) was analysed by RT-PCR, immunohistochemical and Western blot analyses.
Results:
DMBA treated animals developed buccal pouch carcinomas that displayed increased expression of p21, cyclin D1, GST-P, NF-&#954;B, cytokeratins, VEGF and Bcl-2 with decreased expression of Bax, cytochrome C, caspase-3, caspase-9, and PARP. Dietary administration of both P-B and BTF-35 reduced the incidence of DMBA-induced HBP carcinomas by modulating markers of cell proliferation, cell survival, tumour infiltration, angiogenesis, and apoptosis.
Conclusion:
The results of the present study provide a mechanistic basis for the chemopreventive potential of black tea polyphenols. The greater efficacy of BTF-35 in inhibiting HBP carcinogenesis and modulating multiple molecular targets may have a potential role in the prevention of oral cancer.</description>
			<link>http://www.carcinogenesis.com/content/6/1/19</link>
			
			 	<dc:creator>Paramasivame Vidjaya Letchoumy, Kurapathy Venkata Poorna Chandra Mohan, Duvuru Prathiba, Yukihiko Hara and Siddavaram Nagini</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2007, 6:19</dc:source>
			<dc:date>2007-12-03</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-6-19</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>19</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-12-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.carcinogenesis.com/content/6/1/18">
            
            <title>Prolactin, TNF alpha and nitric oxide expression in nitroso-N-methylurea-induced-mammary tumours</title>
			<description>Background:
The N-Nitrosomethylurea breast cancer model induced in rats is used for the study of carcinogenesis in mammary cancer, prostate, pancreas, etc. This model is very similar to human neoplastic disease.
Methods:
The present experimental study was designed to assess whether metoclopramide administration has any effect on development of MNU-induced tumours, and evaluate the treatment of goserelin acetate on PRL, TNF alpha and NO expression. NMU was administered to female Wistar rats on 2 occasions (5 mg/100 g body w/rat). PRL and TNF alpha were performed by immune-assay. Nitric Oxide by semi automated-assay and ploidy analyses by flow cytometry.
Results:
The administration of metoclopramide made the induction time shorter and increased the incidence and average of tumours per rat. Tumours development was inhibited by a goserelin chronic administration. The ploidy of adenocarcinoma was polyploid-aneuploid type (average S = 60%). It was higher basal PRL plasma levels in rats with NMU induced tumours than in basal controls without tumour (p &lt; 0.001). The goserelin "in bolus" administration showed maximal inhibition of plasma PRL at 90 min. Plasmatic TNF alpha expression was inhibited at 60 min and also remained inhibited in tissue homogenate post chronic treatment (P &lt; 0.0125). Plasmatic NO expression is higher in rats with induced tumours than healthy controls (P &lt; 0.001). In tissue homogenate NO values were inhibited at 90 min (P &lt; 0.01), as well during chronically goserelin treatment (P &lt; 0.005).
Conclusion:
The increase of blood PRL levels in NMU-induced rats may be an indicator of a poor prognosis of mammary cancer evolution. The metoclopramide administration accelerates tumour growth. However goserelin administration achieves regression in tumour development associated to inhibition PRL, TNF alpha and NO expression.</description>
			<link>http://www.carcinogenesis.com/content/6/1/18</link>
			
			 	<dc:creator>Irene Vegh and Rafael Enr&#237;quez de Salamanca</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2007, 6:18</dc:source>
			<dc:date>2007-11-28</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-6-18</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>18</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.carcinogenesis.com/content/6/1/17">
            
            <title>The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production</title>
			<description>Background:
Cyclooxygenase-2 (COX-2) expression has previously been identified in uveal melanoma although the biological role of COX-2 in this intraocular malignancy has not been elucidated. This study aimed to investigate the effect of a COX-2 inhibitor on the proliferation rate of human uveal melanoma cells, as well as its effect on the cytotoxic response of macrophages.
Methods:
Human uveal melanoma cell lines were transfected to constitutively express COX-2 and the proliferative rate of these cells using two different methods, with and without the addition of Amfenac, was measured. Nitric oxide production by macrophages was measured after exposure to melanoma-conditioned medium from both groups of cells as well as with and without Amfenac, the active metabolite of Nepafenac.
Results:
Cells transfected to express COX-2 had a higher proliferation rate than those that did not. The addition of Amfenac significantly decreased the proliferation rate of all cell lines. Nitric oxide production by macrophages was inhibited by the addition of melanoma conditioned medium, the addition of Amfenac partially overcame this inhibition.
Conclusion:
Amfenac affected both COX-2 transfected and non-transfected uveal melanoma cells in terms of their proliferation rates as well as their suppressive effects on macrophage cytotoxic activity.</description>
			<link>http://www.carcinogenesis.com/content/6/1/17</link>
			
			 	<dc:creator>Jean-Claude Marshall, Amanda L Caissie, Stephanie R Cruess, Jonathan Cools-Lartigue and Miguel N Burnier</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2007, 6:17</dc:source>
			<dc:date>2007-11-27</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-6-17</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>17</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.carcinogenesis.com/content/6/1/16">
            
            <title>RKIP does not contribute to MAP kinase pathway silencing in the Merkel Cell Carcinoma cell line UISO</title>
			<description>Background:
The Raf kinase inhibitor protein (RKIP) has been shown to block MAP kinase pathway as well as NF&#954;B signalling. By means of immunohistochemistry, we previously demonstrated that the MAP kinase pathway is virtually inactive in Merkel cell carcinoma (MCC). Similarly to MCC in situ high RKIP expression accompanies absence of ERK phosphorylation in the MCC cell line UISO suggesting that RKIP might be causative for MAP kinase pathway silencing.
Methods:
Applying an siRNA approach RKIP expression was knocked down in UISO cells and a possible influence on MAP kinase pathway activity was assessed by Western blot analysis using phospho-specific antibodies. Moreover, a possible effect of RKIP knock down in UISO cells on proliferation as well as chemosensitivity to cisplatin were examined applying the MTS assay.
Results:
Surprisingly the absence of phosphorylation of the MAP kinases ERK1 and ERK 2 even following growth factor stimulation was not affected by the RKIP knock down indicating that RKIP is not essential for blocking the MAP kinase pathway in the MCC cell line UISO. Moreover, proliferation as well as chemosensitivity towards cisplatin were not altered upon knock down of RKIP.</description>
			<link>http://www.carcinogenesis.com/content/6/1/16</link>
			
			 	<dc:creator>Roland Houben, Sonja Ortmann and Juergen C Becker</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2007, 6:16</dc:source>
			<dc:date>2007-10-24</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-6-16</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-10-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.carcinogenesis.com/content/6/1/15">
            
            <title>Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomas</title>
			<description>Background:
Neuroblastoma (NB) is the most common extracranial solid tumour of childhood. Several genomic imbalances correlate to prognosis in NB, with structural rearrangements, including gene amplification, in a near-diploid setting typically signifying high-risk tumours and numerical changes in a near-triploid setting signifying low-risk tumours. Little is known about the temporal sequence in which these imbalances occur during the carcinogenic process.
Methods:
We have reconstructed the appearance of cytogenetic imbalances in 270 NBs by first grouping tumours and imbalances through principal component analysis and then using the number of imbalances in each tumour as an indicator of evolutionary progression.
Results:
Tumours clustered in four sub-groups, dominated respectively by (1) gene amplification in double minute chromosomes and few other aberrations, (2) gene amplification and loss of 1p sequences, (3) loss of 1p and other structural aberrations including gain of 17q, and (4) whole-chromosome gains and losses. Temporal analysis showed that the structural changes in groups 1&#8211;3 were acquired in a step-wise fashion, with loss of 1p sequences and the emergence of double minute chromosomes as the earliest cytogenetic events. In contrast, the gains and losses of whole chromosomes in group 4 occurred through multiple simultaneous events leading to a near-triploid chromosome number.
Conclusion:
The finding of different temporal patterns for the acquisition of genomic imbalances in high-risk and low-risk NBs lends strong support to the hypothesis that these tumours are biologically diverse entities, evolving through distinct genetic mechanisms.</description>
			<link>http://www.carcinogenesis.com/content/6/1/15</link>
			
			 	<dc:creator>David Gisselsson, Gisela Lundberg, Ingrid &#216;ra and Mattias H&#246;glund</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2007, 6:15</dc:source>
			<dc:date>2007-09-26</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-6-15</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>15</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-09-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.carcinogenesis.com/content/6/1/14">
            
            <title>The association between paternal prostate cancer and type 2 diabetes</title>
			<description>ObjectiveIncreasing evidence indicates that type 2 diabetic patients are at elevated risk for developing different kinds of cancers. However, diabetes mellitus may be a protective factor for prostate cancer since both were found to be negatively associated. Based on the same genetic background, parents of diabetic patients might show similar risks concerning cancers.Research design and methodsWe conducted a case-control study, where familiy history of 794 type 2 diabetic cases and 775 non-diabetic controls was ascertained. Then, we expanded our study up to 801 type 2 diabetic cases and 1267 non-diabetic controls.
Results:
Concerning the 794 type 2 diabetic patients and 775 controls, we observed that cancer of cervix uteri was elevated among mothers of controls (odds ratio (OR) 0.19; 95% confidence interval (CI) 0.02 to 0.88; p = 0.033). Mothers of diabetic patients showed an increased history of cancers of the liver and biliary tract (OR 5.23; 95% CI 1.87 to 19.9; p = 0.0009) and stomach (OR 3.84; 95% CI 1.47 to 12.4; p = 0.0049). Pancreatic cancers were found to be elevated in fathers of diabetic patients (OR 4.92; 95% CI 1.07 to 46.7; p = 0.039). Most notably, a lower number of prostate cancers was observed in fathers of diabetic patients (OR 0.47; 95% CI 0.22 to 0.94; p = 0.032). Since diabetic patients were 14.3 years older than the controls, higher levels of cancer history among parents of diabetic patients would have been expected. Thus, the observed lower level of history of prostate cancer can be regarded as highly reliable.The analysis of 801 type 2 diabetics and 1267 controls showed that cancer of stomach was elevated among mothers of controls (OR 2.67; p = 0.0106). In addition, stomach cancers were found to be elevated in fathers of diabetic patients (OR 2.10; p = 0.0141). In accordance with the previous investigation, we again obseved a lower number of prostate cancers in fathers of diabetic patients (OR 0.49; p = 0.0279).However, the application of the statistical method of Mantel-Haenszel showed no significant result concerning any of the cancer histories.
Conclusion:
Fathers of patients suffering from type 2 diabetes were diagnosed less frequently with prostate cancer compared to fathers of non-diabetic controls. As first-degree relatives, e.g. diabetic patients and their fathers, share 50% of their genes, it appears plausible that genetic factors may play an important role in the negative association between diabetes and prostate cancer. However, different statistic analyses showed controversial results concerning the effect of type 2 diabetes on prostate cancers.</description>
			<link>http://www.carcinogenesis.com/content/6/1/14</link>
			
			 	<dc:creator>Peter Meyer, Christine Zuern, Norbert Hermanns and Thomas Haak</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2007, 6:14</dc:source>
			<dc:date>2007-09-26</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-6-14</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-09-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.carcinogenesis.com/content/6/1/13">
            
            <title>The role of GSTM1 gene polymorphisms in lung cancer development in Turkish population</title>
			<description>Background:
Glutathione S-transferase (GSTs) plays an important role in the detoxification of many xenobiotics involved in the etiology of cancer. In different ethnic groups, variations in null allele frequency have been observed. We have investigated GSTM1 gene polymorphisms in healthy subjects and lung cancer patients in the Turkish population and reviewed the control subjects of the studies performed in the Turkish population.
Methods:
Following blood sampling from patients and controls, DNA samples were extracted from the whole blood and were amplified by using polymerase chain reaction (PCR) method in all of the 256 cases, consisting of 102 previously diagnosed with lung cancer and 154 healthy controls.
Results:
The prevalence of GSTM1-null genotype in the lung cancer patients was 49%, compared to 52.6% in the control group (OR = 1.39, 95% CI = 0.70&#8211;1.90, p = 0.57). There were also no significant relationships in GSTM1 genotypes among histopathologic types of lung cancers (p > 0.05). The frequency of GSTM1 was found to be 41.2% (n = 1809) when the control subjects of the studies performed in Turkish population were reviewed.
Conclusion:
We have observed that GSTM1 genotype is not an independent risk factor for lung cancer.</description>
			<link>http://www.carcinogenesis.com/content/6/1/13</link>
			
			 	<dc:creator>Adalet Demir, Sedat Altin, Davut Pehlivan, Mulahim Demir, Fatih Yakar, Ekrem Cengiz Seyhan and Seyyit Ibrahim Dincer</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2007, 6:13</dc:source>
			<dc:date>2007-09-26</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-6-13</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-09-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.carcinogenesis.com/content/6/1/12">
            
            <title>Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis</title>
			<description>Background:
Breast cancer accounts for 30.3% of all cancer types in Kuwaiti women. Death occurs in approximately 43% of these patients. Our goal was to conduct a comprehensive analysis of the pathobiological characteristics of the tumours in an attempt to determine any particular trend that could be present.
Methods:
One hundred and sixty-six cases were included in this study. All the pathology reports and paraffin blocks pertaining to these cases were collected. Four micrometer sections were taken from each block, and immunostaining against Her-2, ER, and PgR was performed. Both the proportion and intensity of immunostaining were scored according to the Allred's method, and typing of the tumour was done according the WHO criteria regarding tumour classification. Grading of invasive carcinomas was done according to the modified Bloom-Richardson-Elston's method, and tumour stage was determined according to the criteria set by the American Joint Committee on Cancer.
Results:
The mean age of the patients below 55 years was 40, as compared to 68 for those above 55 (p &lt; 0.0001). More than half of the cases were in the right breast, and were surgically treated by total mastectomy with axillary clearance. The majority of the tumours had irregular (stellate) margins, was invasive, and had a surrounding breast tissue of adenosis or fibrocystic type. Their mitotic index was 10&#8211;20 or >20 with a marked to moderate nuclear pleomorphism. They were mostly grade II or III, sized 2&#8211;5 or > 5 cm, had absent or scanty tumour lymphocytes, and were stage II or III. The in situ tumours were mainly ductal carcinoma (DCIS) of which comedo and cribriform were the major histological subtypes. The major histological subtypes of the invasive tumours were ductal-not otherwise specified, lobular, and tubular/cribriform. In this study, we also found a significant (p &lt; 0.05) association between over expression of Her-2, lack of expression of ER and some of the characteristics mentioned above.
Conclusion:
Breast cancer in Kuwait seems to be more aggressive than what is currently seen in Europe, North America, Australia, and parts of Asia. Further investigations regarding the features observed in this study need to be performed.</description>
			<link>http://www.carcinogenesis.com/content/6/1/12</link>
			
			 	<dc:creator>Farid Saleh and Suad Abdeen</dc:creator>
			
			<dc:source>Journal of Carcinogenesis 2007, 6:12</dc:source>
			<dc:date>2007-09-24</dc:date>
			<dc:identifier>doi:10.1186/1477-3163-6-12</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Carcinogenesis</prism:publicationName>
					
			
							
					<prism:issn>1477-3163</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>12</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-09-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
